In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein

Background Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conse...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Genetic Engineering and Biotechnology 2022-06, Vol.20 (1), p.89-13, Article 89
Main Authors: Nelluri, Kanaka Durga Devi, Ammulu, Manne Anupama, Durga, M. Lakshmi, Sravani, Melika, Kumar, Vemuri Praveen, Poda, Sudhakar
Format: Article
Language:English
Subjects:
Antigenic determinants
Bunyumwera virus
Genetic vectors
Health aspects
India
Medical research
Medicine, Experimental
Molecular dynamics
Mortality
Multi-epitope
Nucleocaspid N-Protein
Povidone
T cells
Vaccination
Vaccine design
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conservancy. For creating the most potent immunological response possible, docking epitopes with HLA alleles are chosen to screen them. The 3D vaccination was docked with the Toll-like receptor-8 using molecular dynamic simulations. To ensure production efficiency, the vaccine sequence was further cloned in silico in a plasmid pIB2 vector. For efficacy and safety, results must be supported in vitro and in vivo. Results The vaccine was cloned to enable expression and translation in a plasmid vector pIB2. It was expected to be antigenic, non-allergenic, and have a high binding affinity with TLR-8 in silico cloning. This multi-epitope vaccination may stimulate both innate and adaptive immunity. Conclusion The vaccine developed in this work was based on the nucleocapsid N-protein of the Bunyumwera virus and was created using a reverse vaccinology method. Further experimental validation is required to assess the vaccine's therapeutic effectiveness and immunogenicity.
ISSN:1687-157X
2090-5920
DOI:10.1186/s43141-022-00355-y